Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)

NCT04472429 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04472429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04472429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
November 9, 2020
Completion date
September 26, 2025
Enrollment
308 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the anal canal